BioXcel Therapeutics, Inc. BioXcel Therapeutics, Inc.

  • About
    • Overview
    • Management Team
    • Board of Directors
    • Strategic Advisors
  • Product Pipeline
    • Overview
    • Expanded Access
  • News & Media
    • Press Releases
    • Publications
    • Events
    • Media
  • Investors
    • Investor Relations
    • Overview
    • News / Events
    • Overview
    • Press Releases
    • Press Coverage
    • IR Calendar
    • Email Alerts
    • Company Info
    • Overview
    • Presentations
    • Management Team
    • Contacts
    • FAQ
    • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
    • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Business Development
  • Careers
    • Overview
    • Job Openings
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Publications
  • Events
  • Media

BioXcel Therapeutics Reports Fourth Quarter and Full Year 2018 Quarterly Results and Provides Business Update

Mar 7, 2019

BioXcel Therapeutics to Participate in Upcoming Investor Conferences in March

Mar 5, 2019

BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer

Mar 4, 2019

BioXcel Therapeutics to Host Fourth Quarter & Full Year 2018 Financial Results and Business Update Conference Call

Mar 1, 2019

BioXcel Therapeutics to Present at 2019 BIO CEO & Investor Conference

Feb 6, 2019

BioXcel Therapeutics Expands Indication for Lead Neuroscience Asset, BXCL501, to Treat Symptoms Associated with Opioid Drug Withdrawal

Feb 4, 2019

BioXcel Therapeutics Reports Positive Human Proof-of-Concept Data for Acute Treatment of Agitation in Patients with Alzheimer’s Disease

Jan 3, 2019

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL501 for Acute Treatment of Agitation

Dec 27, 2018

BioXcel Therapeutics Doses First Subjects in Pharmacokinetic (Bioavailability) and Safety Study of BXCL501 for the Acute Treatment of Agitation

Dec 19, 2018

BioXcel Therapeutics Announces FDA Acceptance of IND for Lead Neuroscience Candidate, BXCL501 for the Acute Treatment of Agitation

Dec 12, 2018
    • 1...
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • ...15
    © 2021 BioXcel Therapeutics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap